Cerevel Therapeutics

Cerevel Therapeutics was an American biotechnology and pharmaceutical company established in October 2018 through a collaboration between Pfizer and private-equity firm Bain Capital. It was created to pursue medicines for disorders of the brain and nervous system, an area characterized by complex disease biology, substantial unmet medical need, and historically high development risk. The company was headquartered in Cambridge, Massachusetts. Cerevel’s research strategy centered on understanding the neural circuits and receptor systems involved in disease. Rather than treating psychiatric and neurological conditions as broad, undifferentiated categories, the company described its approach as identifying the relevant neurocircuitry, selecting the receptor subtypes most closely connected to the disease mechanism, and designing medicines capable of modulating those targets with greater precision. Its pharmacological work included full and partial agonists, antagonists, and allosteric modulators intended to influence brain signaling while limiting unwanted off-target effects. The company’s development portfolio covered several therapeutic areas, including schizophrenia, Parkinson’s disease, epilepsy, mood disorders, dementia-related apathy, and substance-related disorders. Among the better-known investigational programs were tavapadon for Parkinson’s disease; emraclidine for schizophrenia and Alzheimer’s disease; darigabat for epilepsy; CVL-871 for dementia-associated apathy; and CVL-354 for major depressive and substance-related disorders. These programs were at different stages of development, and the available reference material does not establish that any of them had become commercially approved products under the Cerevel name. In 2019, Cerevel appointed N. Anthony Coles as chief executive officer. Under Coles’s leadership, the company pursued capital formation and in 2020 raised $445 million in a public listing intended to fund the development of brain medicines. The transaction was described as the third-largest biotechnology public listing at that time, after listings associated with Legend Biotech and Moderna. Coles left the chief executive position in May 2023 but remained chairman of Cerevel’s board. Cerevel’s independent corporate period ended when AbbVie announced in December 2023 that it intended to acquire the company for approximately $8.7 billion. The transaction was completed in August 2024. Cerevel subsequently became an AbbVie subsidiary, marking a transition from an independently operated biotechnology company to a neuroscience-focused business within a major pharmaceutical group. Its significance therefore lies both in its pipeline of central-nervous-system medicines and in its role as an acquired specialist platform within AbbVie’s broader pharmaceutical operations.

Cerevel Therapeutics was established in October 2018 through a collaboration between Pfizer and Bain Capital. The company was organized around the discovery and development of medicines for psychiatric and neurological illnesses, with a particular emphasis on disorders involving the brain’s complex signaling networks. Its creation combined pharmaceutical-sector resources with private-equity backing and gave the new company a focused platform for neuroscience research. Cerevel’s scientific identity was based on a circuit- and receptor-oriented view of drug development. The company sought to understand the neural circuitry associated with a disease, identify receptor subtypes connected to the relevant physiology, and then design compounds that could modulate those targets selectively. Its stated pharmacological toolkit included full and partial agonists, antagonists, and allosteric modulators. The intended benefit of this approach was to influence disease-relevant signaling while reducing unnecessary activity at unrelated receptors and thereby limiting undesirable effects. The company’s pipeline addressed a range of central-nervous-system conditions. Tavapadon was associated with Parkinson’s disease. Emraclidine was developed for schizophrenia and was also associated with Alzheimer’s disease research. Darigabat was an epilepsy program, while CVL-871 was linked to dementia and apathy. CVL-354 was associated with major depressive and substance-related disorders. These assets represented a pipeline rather than a portfolio of established commercial products, and they were at varying stages of development. In 2019, Cerevel appointed N. Anthony Coles as chief executive officer. During his tenure, the company raised $445 million in 2020 for the development of brain medicines. The financing occurred through a biotechnology public listing that was described as the third-largest of its kind at the time, following listings associated with Legend Biotech and Moderna. This capital raise gave Cerevel resources to advance its neuroscience programs and helped establish the company as a significant specialist biotechnology enterprise. Coles resigned as chief executive in May 2023 but continued as chairman of the board. Later that year, AbbVie announced its intention to acquire Cerevel for approximately $8.7 billion. The proposed transaction reflected the pharmaceutical value placed on Cerevel’s neuroscience pipeline and on potential access to medicines addressing psychiatric and neurological disease. AbbVie completed the acquisition in August 2024, and Cerevel became an AbbVie subsidiary. The transaction ended Cerevel’s period as an independent public biotechnology company while preserving its identity as a neuroscience-focused business within AbbVie.

• 2024

  Acquisition by AbbVie is completed

  [1]Cerevel Therapeuticsen.wikipedia.org

  AbbVie completed the acquisition in August 2024, making Cerevel a subsidiary.

• 2023

  Chief executive transition

  [1]Cerevel Therapeuticsen.wikipedia.org

  N. Anthony Coles resigned as chief executive in May but retained the role of board chairman.

• 2023

  AbbVie announces planned acquisition

  [1]Cerevel Therapeuticsen.wikipedia.org

  AbbVie announced plans in December to acquire Cerevel for approximately $8.7 billion.

• 2020

  Cerevel raises $445 million

  [1]Cerevel Therapeuticsen.wikipedia.org

  The company raised $445 million in a biotechnology public listing to support development of medicines for brain disorders.

• 2019

  N. Anthony Coles becomes chief executive

  [1]Cerevel Therapeuticsen.wikipedia.org

  Cerevel appointed N. Anthony Coles as its chief executive officer.

• 2018

  Cerevel Therapeutics is established

  [1]Cerevel Therapeuticsen.wikipedia.org

  Cerevel was formed in October 2018 through a collaboration between Pfizer and Bain Capital to develop therapies for psychiatric and neurological illnesses.

A neuroscience-focused biotechnology company seeking to develop precisely targeted medicines by linking disease-related neural circuits with selected receptor subtypes.

• Parkinson's disease therapy

  Tavapadon

  Tavapadon was a Cerevel investigational medicine directed at Parkinson’s disease. It was one of the company’s principal movement-disorder programs and formed part of its broader effort to develop therapies that act on selected brain receptors and neural circuits.

• Schizophrenia and Alzheimer's disease therapy

  Emraclidine

  Emraclidine was an investigational neuroscience compound associated primarily with schizophrenia development and also with research related to Alzheimer’s disease. It represented Cerevel’s effort to pursue receptor-selective approaches in serious psychiatric and neurological conditions.

• Epilepsy therapy

  Darigabat

  Darigabat was an investigational medicine in Cerevel’s epilepsy pipeline. The program reflected the company’s focus on designing compounds intended to modulate specific central-nervous-system targets rather than relying on broad, nonspecific brain activity.

• Dementia-related apathy therapy

  CVL-871

  CVL-871 was an investigational program associated with dementia and apathy. It addressed a behavioral and functional aspect of neurological disease within Cerevel’s broader pipeline of brain-focused therapies.

• Mood and substance-related disorder therapy

  CVL-354

  CVL-354 was an investigational Cerevel compound associated with major depressive and substance-related disorders. Its inclusion in the pipeline demonstrated the company’s interest in psychiatric indications alongside neurological diseases.

• 2023

  Agree to AbbVie acquisitionM&A

  Background

  AbbVie sought to acquire Cerevel and its neuroscience-focused development portfolio.

  Action taken

  AbbVie announced its intention to acquire Cerevel for approximately $8.7 billion.

  Aftermath

  The transaction closed in August 2024, and Cerevel became an AbbVie subsidiary.

  Announced acquisition value. $8.7 billion (Announced December 2023; completed August 2024)

  Source

• 2020

  Raise capital through a public biotechnology listingStrategy

  Background

  Cerevel needed capital to advance a pipeline of medicines for brain disorders.

  Action taken

  The company raised $445 million through a public listing.

  Aftermath

  The financing supported Cerevel’s development activities and was described as the third-largest biotechnology public listing at that time.

  Capital raised. $445 million (2020)

  Source

• 2020.10.28

  Reported2020.10.28

  Cerevel Therapeutics begins trading on Nasdaq[2]Cerevel Therapeutics开始在纳斯达克交易biospace.com

  Cerevel Therapeutics began trading on the Nasdaq on October 28, 2020, after its business combination with Arya Sciences Acquisition Corp II. The article reports net proceeds of about $440 million from the transaction.

Read more

1. 1Cerevel Therapeuticsen.wikipedia.org
2. 2Cerevel Therapeutics开始在纳斯达克交易biospace.com